Januvia, the diabetes drug by the Merck & Co is found to be effective in improving the blood sugar levels over two years of treatment when combined with the older drug metformin. New studies has shown the results in London. The study has been presented at the European Association for the Study of Diabetes annual conference in Rome.
The mean reduction in HbA1c -- a common measure of blood glucose – in a study involving Januvia 50 mg and metformin 1,000 mg twice-daily was 1.8 percent after the first year and 1.7 percent at two years, researchers told a medical meeting.
It can remembered that the Merck’s Januvia, also known as sitagliptin, annualizes sales of $1.6 billion some two years after launch.
Bernard Charbonnel of the University Hospital in Nantes, France,
“This is important for patients and physicians because type 2 diabetes is characterized by a progressive deterioration in beta cell function over time, resulting in the disease worsening.”
Dipeptidyl peptidase-4 (DPP-4) inhibitors work to enhance the body’s ability to lower elevated levels of blood sugar.